DEA assigns Schedule V status to cannabis-based Epidiolex!

DEA assigns Schedule V status to cannabis-based Epidiolex!

Here’s an upgrade everybody within the medical cannabis community happens to be awaiting: the U.S. Drug Enforcement management has provided cannabis-derived medication Epidiolex a Schedule V classification today.

This is actually the time that is first cannabis-based medicine happens to be rescheduled in the usa.

What exactly is Epidiolex, exactly?

Epidiolex can be a dental prescription medication manufactured by U.K.-based GW Pharmaceuticals PLC. It had been formulated to take care of two serious forms of epilepsy in patients over couple of years old. Those two uncommon kinds of epilepsy are Dravet problem and Lennox-Gastaut syndrome, both seen as an regular and seizures that are hard-to-treat.Continue reading